The approval allows treatment of heart failure patients irrespective of the ejection fraction based on new trial DELIVER conducted by AstraZeneca AstraZeneca Pharma India Ltd. (AstraZeneca India), a science-led biopharmaceutical company, announced it has received extended indication approval from the Drugs Controller General of India